Arbitration ruling over BASF claims is imminent: Bayer
Frankfurt: Bayer's chief executive said an arbitration court would soon decide on claims brought by rival BASF, saying it overpaid for assets that Bayer sold to secure antitrust clearance for the takeover of Monsanto.
Bayer CEO Werner Baumann told analysts in a call on Thursday that the ruling was expected "shortly" and that there was hardly any potential to seek recourse should Bayer disagree with the verdict.
BASF in 2019 took Bayer to a previously agreed arbitration court, claiming that Bayer had not fully disclosed personnel costs when it negotiated the sale of two assets bundles.
To secure the eventual antitrust clearance for Bayer's 2018 takeover of Monsanto, Bayer in 2017 agreed to sell certain seed and herbicide assets for 5.9 billion euros ($6.02 billion) to BASF, followed by the sale of its global vegetable seeds business, certain seed treatments and digital farming activities for up to 1.7 billion euros.
Read also: Bayer to sell Nebido to Grünenthal for over Rs 4051 crore
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.